Robert Li

Robert Li has over 20 years of work experience in the pharmaceutical industry. In 2000, they began their career at Novartis China as a Product Manager in Regulatory Affairs. From 2003-2009, they worked at BC Cancer as a Lab Manager, then at Roche Pharmaceuticals as a Postdoctoral Research Scientist. In 2010, they joined Bristol-Myers Squibb as a Senior Research Investigator. From 2014-2019, they worked at Genentech in various roles, including Immunology Therapeutic Area Lead - Safety Assessment, Senior Scientist/Toxicologist, Pharmacology Sub-team Leader, and Scientist/Toxicologist. In 2020, they joined LintonPharm Co., Ltd as a Board Director and Chief Executive Officer. Most recently, in 2022, they became the Co-founder and CEO of LTZ Therapeutics, and also the Chairman of The Board of Directors.

Robert Li completed their education history with a Doctor of Philosophy (Ph.D.) in immunotoxicology from the University of Toronto from 2005 to 2009. Prior to that, they obtained a Master of Science (M.Sc.) in molecular biology in carcinogenesis from Simon Fraser University from 2001 to 2003. Robert also completed a Bachelor of Science (B.Sc.) in Biochemistry & molecular biology from Lanzhou University from 1994 to 1998. In addition, Robert Li obtained a Diplomate of the American Board of Toxicology (DABT) certification from the American Board of Toxicology, Inc. in November 2015.